...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China
【24h】

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China

机译:耐吡嗪酰胺结核病的发生和遗传特征的多中心研究

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to investigate the epidemiology of pyrazinamide (PZA) resistance and the associated risk factors as well as to evaluate the pncA gene loci as a marker for PZA resistance in China. A population-based multicenter study of pulmonary tuberculosis (TB) cases was carried out from 2011 to 2013 in four Chinese districts/counties with different geographic and socioeconomic features. Testing for multidrug-resistant tuberculosis (MDR-TB) and susceptibility to PZA was done by the proportion method on Lowenstein-Jensen medium and Bactec MGIT 960, respectively. Mutations in the pncA gene were identified by sequencing. Among 878 culture-positive cases, 147 (16.7%) were resistant to PZA, with a significantly higher proportion among MDR isolates than among the first-line drug-susceptible isolates (30.2% versus 7.7%; P< 0.001). In total, 136 isolates had a nonsynonymous pncA mutation, with a comparable diagnostic performance between Beijing family and non-Beijing family as well as between MDR-TB and first-line drug-susceptible TB. Furthermore, the mutations in isolates with high-level PZA resistance (MIC> 500 mg/liter) were observed mainly in three regions of the pncA gene (codons 51 to 76, codons 130 to 142, and codons 163 to 180). Patients with prior treatment history had a significantly higher risk for PZA monoresistance (odds ratio [ OR], 2.86; 95% confidence interval [CI], 1.363 to 6.015) and MDR PZA resistance (OR, 6.47; 95% CI, 3.186 to 13.15), while the additional factors associated with MDR PZA resistance were the patient's age (OR, 1.02; 95% CI, 1.003 to 1.042), lung cavity (OR, 2.64; 95% CI, 1.296 to 5.391). These findings suggest that it is a priority to identify PZA resistance in MDR-TB and that a rapid molecular diagnostic test based on pncA mutations in the Chinese settings where MDR-TB prevalence is high should be developed.
机译:这项研究的目的是调查吡嗪酰胺(PZA)耐药的流行病学及其相关的危险因素,并评估pncA基因位点作为中国PZA耐药的标志物。 2011年至2013年,在四个地理和社会经济特征不同的中国地区/县开展了一项基于人群的肺结核病例多中心研究。通过比例方法分别在Lowenstein-Jensen培养基和Bactec MGIT 960上对耐多药结核病(MDR-TB)和对PZA的敏感性进行了测试。通过测序鉴定pncA基因中的突变。在878例培养阳性的病例中,有147例(16.7%)对PZA有抗药性,MDR分离株中的耐药率显着高于一线药物敏感性分离株(30.2%对7.7%; P <0.001)。总共有136个分离物具有非同义的pncA突变,在北京家庭和非北京家庭之间以及耐多药结核病和一线药物敏感性结核病之间具有可比的诊断性能。此外,主要在pncA基因的三个区域(密码子51至76,密码子130至142和密码子163至180)中观察到具有高水平PZA抗性(MIC> 500 mg / l)的分离株中的突变。有既往治疗史的患者发生PZA单药耐药的几率显着较高(几率[OR]为2.86; 95%置信区间[CI]为1.363至6.015)和MDR PZA耐药(OR为6.47; 95%CI为3.186至13.15) ),而与MDR PZA耐药相关的其他因素是患者的年龄(OR,1.02; 95%CI,1.003至1.042),肺腔(OR,2.64; 95%CI,1.296至5.391)。这些发现表明,确定耐多药结核病中的PZA耐药性是当务之急,在耐多药结核病患病率较高的中国人群中,应开发基于pncA突变的快速分子诊断测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号